Helius Medical Technologies, Inc. Market Research Report
Company Overview
Name
Helius Medical Technologies, Inc.
Mission
Helius is dedicated to developing and expanding treatment options that use noninvasive platform technologies to increase patient independence and improve the quality of life for individuals affected by functional neurological deficits.
Foundation
Helius has its origins in the early 1990s, with pioneering work in neuroplasticity at the Tactile Communication and Neurorehabilitation Laboratory (TCNL) at the University of Wisconsin-Madison.
Key People
No specific key people data is provided.
Headquarters
No information is available.
Number of Employees
No information is available.
Revenue
No information is available.
Known For
Helius is known for its work in the neurotech sector, particularly with non-implantable devices that promote neuroplasticity to aid individuals with neurological diseases.
Products
PoNS® Device
Helius offers the Portable Neuromodulation Stimulator (PoNS®), a non-invasive medical device designed to treat gait and balance deficit in individuals with neurological disorders.
Description
The PoNS device provides mild stimulation to the tongue, creating neural impulses sent to brain structures controlling motor functions. This encourages neuromodulation and neuroplasticity when used alongside therapeutic exercises, aiding motor function improvement.
Key Features
- Non-invasive Neuromodulation: Stimulates cranial nerves via the tongue to promote brain communication and activity.
- Promotes Neuroplasticity: Facilitates neural pathway development to improve or regain motor function control.
- Multi-condition Approval: Authorized for treating gait deficit due to Multiple Sclerosis (MS) in the US and Canada, and available for other neurological conditions in Canada and Australia.
Recent Developments
New Products
No information is available about new product launches.
Recent Initiatives
- Reimbursement Determination: The PoNS Mouthpiece has a set reimbursement at $2,963.30 (as of October 2024).
- PoNSSTEP: An open-label research trial assessing adherence to PoNS Therapy for MS patients.
- Stroke Program: Initiated an open-label study for stroke treatment, leveraging real-world evidence from Canada.
New Features
No specific new features for existing products are provided.
Partnerships
- Québec Ministry of Health: Acquiring PoNS devices to assess treatment value for stroke patients.
- University of Montreal: Acquiring PoNS devices for research in stroke recovery.
Additional Information
Clinical Trials
Helius is actively conducting clinical trials to study the effectiveness of PoNS Therapy for various neurological conditions, including multiple sclerosis and traumatic brain injury, and has plans to explore its efficacy in Parkinson's Disease and other mobility-impairing conditions.
Patient Testimonials
Positive outcomes from PoNS Therapy have been reported by patients, with improvement in balance and motor skills, enhancing their daily activities and quality of life.
Regulatory Approvals
PoNS received multiple authorizations, including FDA breakthrough designations and commercialization permissions across different regions for various therapeutic conditions.
This report provides insights into Helius Medical Technologies' operations, focus areas, and impacts on patient care in neuromodulation and neurorehabilitation sectors.
